Investors 

Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris

 

 

Press Releases

22/05/2017

Genomic Vision to enter into technological collaboration with AstraZeneca in oncology

plus_blue pdf_red

 

15/05/2017

Report of the IVD R&D Day of 10 May 2017

plus_blue pdf_red

 

10/05/2017

Genomic Vision announces promising preliminary results for its clinical study in cervical cancer detection

plus_blue pdf_red
 

09/05/2017

Financial information at March 31, 2017

plus_blue pdf_red

 

20/04/2017

Genomic Vision hosts inaugural R&D day with its long-standing partner Quest Diagnostics

plus_blue pdf_red

 

29/03/2017

Issuance of all the warrants for convertible notes with warrants (BEOCABSA) 

plus_blue pdf_red

 

01/03/2017

2016 annual results in line with the successful execution of the new strategy in LSR market

plus_blue  pdf_red

 

09/01/2017

Financial information at December 31st, 2016

plus_blue  pdf_red

 

28/10/2016

Financial information at September 30, 2016 and implementation of a flexible financing via the reserved issuance of convertible notes with warrants

plus_blue  pdf_red

 

20/10/2016

Genomic Vision Presents the Initial Results of the Pilot Study Undertaken with Quest Diagnostics in Spinal Muscular Atrophy (SMA) at the ASHG 2016 Annual Meeting in Vancouver or the first half of 2016

plus_blue   pdf_red

 

26/07/2016

Results for the first half of 2016

plus_blue   pdf_red

 

20/07/2016

Genomic Vision is accelerating its clinical trial in cervical cancer with an additional study in the Czech Republic

plus_blue  pdf_red

 

11/07/2016

Genomic Vision launches EasyScan, the first digital service for analyzing DNA by molecular combing

plus_blue  pdf_red

 

16/06/2016

The clinical trial led by Genomic Vision and Reims University Hospital presented at the Eurogin Congress

plus_blue   pdf_red

 

09/05/2016

Financial information at March 31, 2016

plus_blue  pdf_red

 

23/03/2016

New strategic development area

plus_blue  pdf_red

 

22/03/2016

2015 Annual Results

plus_blue   pdf_red

 

17/03/2016

Genomic Vision obtains NF EN ISO 13485:2012 quality certification

plus_blue  pdf_red

 

10/03/2016

Genomic Vision’s DNA analysis technology singled out in a study published by Nature

plus_blue  pdf_red

 

08/02/2016

Genomic Vision to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference

plus_blue  pdf_red

 

04/02/2016

2016 Financial Calendar

plus_blue  pdf_red

 

18/01/2016

2015 sales in line with expectations after all planned milestones with Quest Diagnostics were met

plus_blue  pdf_red

 

14/01/2016

Genomic Vision to demonstrate ‘molecular combing’ technology’s ability to identify novel cancer-causing BRCA gene variants

plus_blue  pdf_red

 

11/01/2016

Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments

plus_blue  pdf_red

 

14/12/2015

Genomic Vision and Reims University Hospital Launch Clinical Study to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer

plus_blue  pdf_red

 

03/12/2015

Genomic Vision signs a strategic partnership with the Imagine Institute, the largest European genetic research and care cluster

plus_blue  pdf_red

 

01/12/2015

GENOMIC VISION to Present at the LD Micro Main Event

plus_blue  pdf_red

 

12/11/2015

GENOMIC VISION to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

plus_blue  pdf_red

 

22/10/2015

Revenue from 3rd quarter activity up 47%

plus_blue  pdf_red

 

15/10/2015

GENOMIC VISION and ROUEN University Hospital launch a trial to improve genetic counseling for Infantile Spinal Muscular Atrophy in France

plus_blue  pdf_red

 

31/07/2015

2015 first-half results in line with company expectations

plus_blue  pdf_red

 

09/06/2015

Genomic Vision selected for the Horizon 2020 program’s ‘BeyondSeq’ project with a total grant of €6 million

plus_blue  pdf_red

 

06/05/2015

Financial information of the 31st of March 2015 (French)

plus_blue  pdf_red

 

30/04/2015

2014 Financial Report available (French)

plus_blue  pdf_red

 

31/03/2015

Genomic Vision reaffirms its eligibility for the PEA-SME status for 2015/2016 (French)

plus_blue  pdf_red

 

15/03/2015

2014 annual results in line with the Company’s buoyant development

Total revenue from activity: €4.9 million
Operating costs under control
Solid cash position of €22.8 million

plus_blue  pdf_red

 

17/02/2015

Genomic Vision renews its Strategic Collaboration with Quest Diagnostics for three more years

plus_blue  pdf_red

 

09/02/2015

Financial Agenda 2015

plus_blue  pdf_red

 

15/01/2015

2014 Annual Revenue from Sales at €3.5 Million

plus_blue  pdf_red

 

07/01/2015

Genomic Vision achieves major milestone with delivery of new high-throughput genome analyzer to Quest Diagnostics

plus_blue  pdf_red

 

 

frise

 

genomic_web_visuels_footer_COMPANY